Contract on the Establishment of a Joint Venture on Establishment of the [Company] By and between CASI PHARMACEUTICALS, INC. and Wuxi Jintou Huicun Investment Limited Partnership Wuxi, China November 16, 2018 ContentsCASI Pharmaceuticals, Inc. • March 29th, 2019 • Biological products, (no disgnostic substances)
This Joint Venture Contract (hereinafter referred to as the “Contract”) was entered into in Wuxi, Jiangsu, P.R.C., on November 16, 2018 by and between:
Lease ContractCASI Pharmaceuticals, Inc. • March 29th, 2019 • Biological products, (no disgnostic substances)
Whereas Party B intends to set up a foreign-funded enterprise (hereinafter referred to as the “Joint Venture”) in Huishan Economic Development Zone in Wuxi, with the Leased Property as the registered domicile of the Joint Venture, which Party A intends to lease to Party B under this Lease Contract. For the purpose of setting up the Joint Venture, Party A and Party B have reached the following terms and conditions (hereinafter referred to as the “Contract”) pursuant to the Contract Law of People’s Republic of China and other applicable laws and regulations.
Memorandum of UnderstandingCASI Pharmaceuticals, Inc. • March 29th, 2019 • Biological products, (no disgnostic substances)
Party A: The Administrative Committee of Wuxi Huishan Economic Development Zone, Jiangsu Province (Hereinafter referred to as “Party A”)
Investment AgreementInvestment Agreement • March 29th, 2019 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
Party A and Party B, in accordance with the relevant laws and regulations of the People's Republic of China, and based on the principles of equality, voluntariness, reasonable expectation of equal compensations, and good faith, have reached the agreement through sufficient consultation and negotiation on Party B's investment in Wuxi Huishan Economic Development Zone, Jiangsu Province.
Shareholders' Agreement between CASI Pharmaceuticals, Inc. and Wuxi Jintou Huicun Investment Enterprise (Limited Partnership) on the Establishment of a Joint Venture in China Wuxi, China November 16, 2018 ContentsShareholders' Agreement • March 29th, 2019 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
The Shareholders’ Agreement (hereinafter referred to as the "Agreement") was made and entered into by the following Parties in Wuxi, China on November 16, 2018 (hereinafter referred to as the "Execution Date"):
Labor ContractCASI Pharmaceuticals, Inc. • March 29th, 2019 • Biological products, (no disgnostic substances) • Beijing
Party A and Party B sign this Contract in accordance with the “Labor Law of the People’s Republic of China”, “Labor Contract Law of the People’s Republic of China” and other relevant laws and regulations on the basis of equality and voluntariness, fairness and impartiality, consensus, honesty and credibility. Both parties shall promise to abide by the items of this contract.
Supplementary AgreementSupplementary Agreement • March 29th, 2019 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances)
Based on the principles of equality, mutual benefit and consorted development, Party A and Party B have reached an agreement on Party B’s being supported with the following preferential policies, which is supplemental to the "Investment Agreement" signed by the Parties, with the actual amount of support subject to the actual investment size and business output forecasts.
